BioGaia AB (publ) (BIOG-B.ST)
SEK 110.5
(0.82%)
SEK 110.5
(0.82%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 302.84 Million SEK | 25.38% |
| 2022 | 241.54 Million SEK | -3.65% |
| 2021 | 250.68 Million SEK | 50.08% |
| 2020 | 167.03 Million SEK | 5.7% |
| 2019 | 158.02 Million SEK | 4.07% |
| 2018 | 151.85 Million SEK | 35.31% |
| 2017 | 112.22 Million SEK | 52.07% |
| 2016 | 73.79 Million SEK | -4.59% |
| 2015 | 77.34 Million SEK | 8.91% |
| 2014 | 71.01 Million SEK | 6.69% |
| 2013 | 66.56 Million SEK | 10.52% |
| 2012 | 60.22 Million SEK | 21.73% |
| 2011 | 49.47 Million SEK | 22.17% |
| 2010 | 40.49 Million SEK | 116.62% |
| 2009 | 18.69 Million SEK | -14.58% |
| 2008 | 21.88 Million SEK | 37.97% |
| 2007 | 15.86 Million SEK | -2.28% |
| 2006 | 16.23 Million SEK | 5.59% |
| 2005 | 15.37 Million SEK | -9.6% |
| 2004 | 17 Million SEK | -19.23% |
| 2003 | 21.05 Million SEK | -37.41% |
| 2002 | 33.63 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 285.11 Million SEK | -12.38% |
| 2024 Q1 | 311.92 Million SEK | 3.0% |
| 2024 Q2 | 325.39 Million SEK | 4.32% |
| 2023 FY | 302.84 Million SEK | 25.38% |
| 2023 Q4 | 302.84 Million SEK | -5.06% |
| 2023 Q1 | 237.13 Million SEK | -1.83% |
| 2023 Q3 | 318.98 Million SEK | 16.73% |
| 2023 Q2 | 273.26 Million SEK | 15.24% |
| 2022 Q3 | 312.52 Million SEK | -7.0% |
| 2022 Q4 | 241.54 Million SEK | -22.71% |
| 2022 FY | 241.54 Million SEK | -3.65% |
| 2022 Q1 | 273.51 Million SEK | 9.11% |
| 2022 Q2 | 336.06 Million SEK | 22.87% |
| 2021 Q1 | 148.5 Million SEK | -11.09% |
| 2021 FY | 250.68 Million SEK | 50.08% |
| 2021 Q2 | 150.84 Million SEK | 1.57% |
| 2021 Q4 | 250.68 Million SEK | 94.52% |
| 2021 Q3 | 128.87 Million SEK | -14.56% |
| 2020 Q3 | 134.3 Million SEK | -12.16% |
| 2020 Q2 | 152.89 Million SEK | -10.4% |
| 2020 Q4 | 167.03 Million SEK | 24.37% |
| 2020 Q1 | 170.64 Million SEK | 7.98% |
| 2020 FY | 167.03 Million SEK | 5.7% |
| 2019 Q1 | 162.09 Million SEK | 6.74% |
| 2019 FY | 158.02 Million SEK | 4.07% |
| 2019 Q4 | 158.02 Million SEK | -13.96% |
| 2019 Q3 | 183.66 Million SEK | 2.03% |
| 2019 Q2 | 180 Million SEK | 11.05% |
| 2018 Q4 | 151.85 Million SEK | 3.29% |
| 2018 Q1 | 118.71 Million SEK | 5.78% |
| 2018 Q2 | 163.63 Million SEK | 37.84% |
| 2018 Q3 | 147.01 Million SEK | -10.16% |
| 2018 FY | 151.85 Million SEK | 35.31% |
| 2017 Q2 | 103.8 Million SEK | -1.86% |
| 2017 FY | 112.22 Million SEK | 52.07% |
| 2017 Q4 | 112.22 Million SEK | 7.28% |
| 2017 Q3 | 104.6 Million SEK | 0.77% |
| 2017 Q1 | 105.77 Million SEK | 43.33% |
| 2016 Q4 | 73.79 Million SEK | -9.88% |
| 2016 FY | 73.79 Million SEK | -4.59% |
| 2016 Q3 | 81.89 Million SEK | 4.14% |
| 2016 Q2 | 78.63 Million SEK | 9.52% |
| 2016 Q1 | 71.8 Million SEK | -7.17% |
| 2015 Q4 | 77.34 Million SEK | -1.0% |
| 2015 Q2 | 88.96 Million SEK | 1.91% |
| 2015 Q3 | 78.12 Million SEK | -12.18% |
| 2015 FY | 77.34 Million SEK | 8.91% |
| 2015 Q1 | 87.29 Million SEK | 22.92% |
| 2014 FY | 71.01 Million SEK | 6.69% |
| 2014 Q2 | 85.01 Million SEK | 15.52% |
| 2014 Q3 | 63.37 Million SEK | -25.46% |
| 2014 Q4 | 71.01 Million SEK | 12.06% |
| 2014 Q1 | 73.59 Million SEK | 10.56% |
| 2013 FY | 66.56 Million SEK | 10.52% |
| 2013 Q1 | 63.72 Million SEK | 5.8% |
| 2013 Q4 | 66.56 Million SEK | 4.52% |
| 2013 Q3 | 63.68 Million SEK | 0.03% |
| 2013 Q2 | 63.66 Million SEK | -0.1% |
| 2012 Q1 | 128.83 Million SEK | 160.4% |
| 2012 Q2 | 114.6 Million SEK | -11.04% |
| 2012 Q4 | 60.22 Million SEK | -28.55% |
| 2012 Q3 | 84.29 Million SEK | -26.45% |
| 2012 FY | 60.22 Million SEK | 21.73% |
| 2011 FY | 49.47 Million SEK | 22.17% |
| 2011 Q2 | 44.27 Million SEK | 26.01% |
| 2011 Q1 | 35.13 Million SEK | -13.25% |
| 2011 Q4 | 49.47 Million SEK | 13.27% |
| 2011 Q3 | 43.68 Million SEK | -1.33% |
| 2010 Q2 | 34.15 Million SEK | 45.89% |
| 2010 Q3 | 37.62 Million SEK | 10.16% |
| 2010 FY | 40.49 Million SEK | 116.62% |
| 2010 Q4 | 40.49 Million SEK | 7.64% |
| 2010 Q1 | 23.41 Million SEK | 25.21% |
| 2009 FY | 18.69 Million SEK | -14.58% |
| 2009 Q4 | 18.69 Million SEK | 0.0% |
| 2009 Q2 | 18.43 Million SEK | 0.0% |
| 2008 FY | 21.88 Million SEK | 37.97% |
| 2007 FY | 15.86 Million SEK | -2.28% |
| 2006 FY | 16.23 Million SEK | 5.59% |
| 2005 FY | 15.37 Million SEK | -9.6% |
| 2004 FY | 17 Million SEK | -19.23% |
| 2003 FY | 21.05 Million SEK | -37.41% |
| 2002 FY | 33.63 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcuCort AB | 10.97 Million SEK | -2659.408% |
| AlzeCure Pharma AB (publ) | 8.22 Million SEK | -3581.111% |
| Enzymatica AB (publ) | 49.3 Million SEK | -514.265% |
| Enorama Pharma AB (publ) | 14.84 Million SEK | -1939.772% |
| Gabather AB (publ) | 6.87 Million SEK | -4303.097% |
| Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | -846.805% |
| Moberg Pharma AB (publ) | 24 Million SEK | -1161.486% |
| Nanexa AB (publ) | 36.42 Million SEK | -731.375% |
| Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | -677.443% |
| ODI Pharma AB | 10.05 Million SEK | -2911.084% |
| Orexo AB (publ) | 727.7 Million SEK | 58.383% |
| Probi AB (publ) | 181.31 Million SEK | -67.024% |
| Swedencare AB (publ) | 2.31 Billion SEK | 86.92% |
| Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 99.246% |
| Toleranzia AB | 6.9 Million SEK | -4283.341% |
| Vivesto AB | 30.45 Million SEK | -894.5% |